 |
|
||||
 |
 |
||||
 |
  |
||||
|
Coapt Systems Launches FDA-Cleared Novielle Voice™ For Restoration Of Voice Loss Coapt Systems New CEO, Laureen DeBuono, To Fuel Company's Growth And Product Innovation Coapt Systems Launches ENDOTINE Ribbon Coapt Systems Launches SurgiWire™ Incisionless Dissector Coapt Systems Launches ENDOTINE Midface™ Bone 4.5 for Vertical Midface Suspension Coapt Systems Launches ENDOTINE® Triple™ Coapt Systems Launches ENDOTINE® TransBleph™ Coapt Systems Secures $12 Million In Series D Venture Funding Coapt Systems Launches ENDOTINE Midface™ ST 4.5 for Midface Suspension Coapt Systems Receives CE Mark for ENDOTINE Forehead Fixation Device Coapt Systems Secures $12 Million In Series C Venture Funding Coapt Systems Announces BETA Release Of The ENDOTINE™ Forehead 3.5 Coapt Systems, Inc. Launches Hydrelle™ a New, FDA-Approved Dermal Filler with Lidocaine for Significant Wrinkle Correction
and Greater Patient Comfort PALO ALTO, Calif., – July 6, 2009 – Coapt Systems, Inc.(www.coaptsystems.com) announced the launch of Hydrelle™ a new, FDA–approved hyaluronic acid based dermal filler for the treatment of facial wrinkles, such as nasolabial folds, also called “smile lines.” Hydrelle is the first FDA–approved hyaluronic acid filler formulated with an anesthetic (lidocaine) for greater patient comfort. Proven safe and effective, Hydrelle is also a financially attractive alternative to traditional fillers such as Juvéderm® by Allergan Medical and Restylane® by Medicis Pharmaceutical. Hydrelle has been specifically formulated to deliver rapid results comparable to other hyaluronic acid fillers; and the lidocaine anesthetic is integrated, providing a more comfortable injection experience for patients. Hydrelle represents an attractive value for patients seeking a safe and cost–effective filler option, since patients only require approximately 50% of typical injection volumes, thus requiring fewer syringes to fully correct facial wrinkles. Hydrelle also represents a significant opportunity for aesthetic professionals to expand their respective practices by offering patients an advanced, long–lasting dermal filler with an affordable price, particularly during volatile economic times. Hydrelle is indicated for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. In a randomized, controlled pivotal U.S. study of 208 patients, Hydrelle was proven safe and effective. In a multi–center, international study, Hydrelle demonstrated patient and physician satisfaction, and filler effectiveness for up to one year. Laureen DeBuono, President and CEO for Coapt Systems stated, “Coapt Systems has established an excellent reputation as a provider of superior, bioabsorbable suspension devices for face lift procedures within the aesthetic marketplace. Now we have a perfect opportunity to compliment our product portfolio with the Hydrelle dermal filler product line.” “Hydrelle represents an important clinical and business distribution milestone between Coapt Systems and the world–class hyaluronic acid product developer and manufacturer, Anika Therapeutics (NASDAQ:ANIK),” said DeBuono. “I look forward to using more Hydrelle and to continuing to offer it to my patients because I have experienced excellent results,” said Michael C. Pickart, M.D., F.A.C.S. “The wrinkle correction is very good compared to competitive products currently on the market, and patients have found Hydrelle to be more comfortable during injection, with less pain. In particular, Hydrelle is definitely my preferred filler of choice for the oral commissures, since they are so hard to numb with dental blocks and topical creams.” Coapt Systems Executive Vice President, Global Marketing and Sales, David Barella stated, “The Coapt Systems sales and marketing team is delighted to introduce Hydrelle to the facial aesthetic community throughout the U.S. I believe that a long–lasting, more comfortable, and cost–effective dermal filler represents a valuable advantage to the millions of women and men that seek to improve their facial appearance every year.” Additionally, Barella said “Physicians will also enjoy the convenient, ready–to–use benefits that Hydrelle with lidocaine offers, without costly and labor intensive pre–injection mixing.” To order Hydrelle, please contact Coapt Systems at 800.963.7670, or visit the worldwide web at www.coaptsystems.com. Hydrelle is available to qualified physicians, or properly licensed practitioners only. About Hydrelle: Hydrelle is the first FDA-approved injectable dermal filler to combine hyaluronic acid and lidocaine, a local anesthetic that improves patient comfort, and provides physicians with a new alternative for their aesthetic practice. Designed, developed and manufactured by Anika Therapeutics, Hydrelle is formulated for durability based on its proprietary cross-linking technology and the highest concentration of hyaluronic acid. Hydrelle is exclusively distributed within the U.S. by Coapt Systems. Hydrelle is indicated for injection into the mid-to-deep dermis for the correction of moderate to severe facial wrinkles and folds (such as nasolabial folds). In clinical studies, adverse events were usually mild to moderate in nature and generally resolved within seven days. The most common side effects were injection site reactions of swelling, redness, bumps, bruising and tenderness. Hydrelle should not be used by patients with severe allergies. For complete patient safety information, please consult the Hydrelle Instructions for Use. About Coapt Systems, Inc: Coapt Systems develops and markets unique facial rejuvenation products that help produce beautifully natural, long-lasting results for forehead, brow, cheek, and neck lifts. Endotine® and Ultratine™ are clinically-proven products that provide face lift patients with minimally invasive treatment and rapid recovery. Novielle™ biocompatible hydrogel injectable fillers can provide immediate voice restoration for patients suffering from vocal fold insufficiency. Coapt Systems is venture-backed and headquartered in Palo Alto, California. For more information, please visit (www.coaptsystems.com.) About Anika Therapeutics, Inc: Headquartered in Bedford, Mass., Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. Anika’s products include ORTHOVISC®, a treatment for osteoarthritis of the knee available internationally and marketed in the U.S. by DePuy Mitek; HYVISC®, a treatment for equine osteoarthritis marketed in the U.S. by Boehringer Ingelheim Vetmedica, Inc.; a family of aesthetic dermatology products for facial wrinkles and scar remediation; AMVISC®, AMVISC® Plus, STAARVISC™–II and Shellgel™ injectable viscoelastic HA products for ophthalmic surgery; INCERT®, an HA–based anti–adhesive for surgical applications; ORTHOVISC® mini a treatment for osteoarthritis targeting small joints and available in Europe; MONOVISC™ a single–injection osteoarthritis product based on Anika’s proprietary cross–linking technology and also available in Europe and Turkey; and next generation products for joint health and aesthetic dermatology based on the Company’s proprietary, chemically modified HA. Coapt Systems Launches FDA–Cleared Novielle Voice™ For Restoration Of Voice Loss For Immediate Release: September 21, 2008 (Palo Alto) California – Coapt Systems Inc. today announced the launch of its Novielle Voice family of injectable fillers at the 112th annual meeting of the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) in Chicago, IL, September 21-24, 2008. The U.S. Food and Drug Administration (FDA) cleared Novielle Voice Gel and Novielle Voice GelPlus earlier this year for restoration of voice loss. Novielle Voice is available in two formulations based on a proprietary, bioabsorbable Acrylomer™ Complex. Novielle Voice is injected into the vocal folds to repair defects that cause the voice to become faint and speaking to become difficult. According to Dr. David Apfelberg, Medical Director for Coapt Systems, "Examples of patients who can be helped by Novielle Voice injections are patients who have experienced damage to nerves in the voice box, stroke, or surgery of the esophagus. We believe many other patient populations, such as those with Parkinson’s disease or presbyphonia, age related loss of voice, can be helped with this simple procedure that can be performed under local anesthesia." Dr. Edward Damrose is conducting a study on the longevity of Novielle Voice in Northern California, and is enthused. "Novielle Voice is a valuable addition to our armamentarium. I am impressed with our preliminary results and I trust that Novielle will prove useful in addressing the longer term needs of our patients." "This is the first product line of a complete family of medical and aesthetic Novielle filler products that we plan to introduce. Novielle Voice works by replacing the lost volume in one or both of the vocal folds to restore voice volume and quality and reduce voice effort,” said David Barella, Senior Vice President, Global Sales and Marketing. Barella added, “While this is not a permanent solution to voice loss, Novielle Voice will enable us to address the needs of patients who could benefit from intermediate duration injectable products." Novielle Voice is available in the United States. To learn more, please visit www.NovielleVoice.com.
About Coapt Systems Coapt Systems Announces Two Key Executive Appointments In Worldwide Marketing, Sales, Research And Development For Immediate Release: September 18, 2008 (Palo Alto) California – Coapt Systems Inc. announced today the appointments of David Barella as Senior Vice President, Global Marketing and Sales, and Bader Bellahsene, PhD, as Vice President, Research, Development and Manufacturing. "I am very pleased that Dave and Bader have joined our executive management team at Coapt. They each have over twenty years of medical device experience, with a deep, broad level of expertise in the global aesthetic marketplace. Their proven track records, strategic leadership and industry knowledge will be invaluable to us as we continue our growth into new technologies, including non-invasive opportunities," commented Laureen DeBuono, President and Chief Executive Officer of Coapt Systems. "Together, we will more deeply penetrate the market with our core products, build the technology platform, and expand our business into new markets." Coapt Systems, founded by a practicing plastic surgeon, develops and markets facial rejuvenation products based on novel technology that produces natural results, reduced recovery time and increased economic value when compared to traditional facelift procedures. In addition, the Company received FDA clearance this year to market a new injectable vocal fold filler, Novielle Voice™, which will be launched September 21, 2008. "Coapt Systems is seen as a leader in facial aesthetic surgery and I am thrilled to be a part of this executive team," said Barella. "This is an exciting time for Coapt as we demonstrate continued market leadership and work to advance our innovations to offer cost-effective aesthetic procedures in the anti-aging market." Barella added, "Coapt provides value and unmatched options in the aesthetics marketplace. This leading-edge technology helps surgeons deliver natural looking facial aesthetic results, with a more rapid recovery, for women and men." "This Company has a compelling new technology platform and our team is committed to the science and innovation required to bring these to market," says Bellahsene. "It is a natural progression for Coapt to grow beyond its expertise in bioabsorbable implants. As such, I am confident we will continue to deliver world class, next generation products to the aesthetic market." Mr. Barella is a global sales and marketing executive with a thirty year record of outstanding sales growth, market share gain and profitability for Fortune-500, as well as privately-held medical device companies. Prior to joining Coapt, Barella was the Executive Vice President, International Sales and Marketing for MediCor Ltd. Integrating international subsidiaries, Eurosilicone and Nagor, Barella led these combined entities to become the #3 market leader in breast, facial and body aesthetic implants outside the United States. Barella began his aesthetics career as Executive Vice President, Worldwide Sales and Marketing for the McGhan Medical Division of INAMED (acquired by Allergan). He initiated the first successfully commercial, direct-to-consumer marketing programs for breast implants and dermal fillers and was instrumental in leading INAMED to become the worldwide leader in facial and body implants. Dr. Bellahsene has a proven track record of developing best-in-class products with nearly twenty years experience in biomedical device research, design and development. Prior to Coapt Systems, Dr. Bellahsene was Vice President of Research and Development at Thermage, advancing their technology and developing a number of products for this leader in non-invasive procedures to tighten and contour skin. Dr. Bellahsene has also held various technical leadership positions at companies including Somnus Medical, Stryker Corporation, BCI International, and Polysens. He holds several U.S. and international patents, and is the author of numerous scientific publications and book chapters.
About Coapt Systems Coapt Systems New CEO, Laureen DeBuono, To Fuel Company's Growth And Product Innovation For Immediate Release: April 30, 2008 (Palo Alto), California –Coapt Systems, Inc., developer of bioabsorbable implants for the fixation of soft tissue in the plastic, reconstructive and sports medicine markets, announced today the appointment of Laureen DeBuono as its President and CEO. She will also serve as a member of the company’s Board of Directors. DeBuono has more than 25 years of management experience in the medical device and technology markets. She was most recently CFO of Thermage, Inc., one of the leading medical device companies for aesthetic applications, where she was instrumental in building its growth platform and taking the company public in November 2006. At Coapt Systems, DeBuono will focus on growing core product revenue, building the technology platform, and expanding into new markets, including non-invasive aesthetics. ”I am thrilled to join Coapt Systems as its President and CEO and to help the company achieve even greater success by taking advantage of new market opportunities,” said DeBuono. ”Coapt has established itself as a market leader and innovator, and the company has steadily increased its product offerings and customer base. Coapt is now poised to expand its innovative product line and to move into new markets, particularly non-invasive aesthetics.” The company has introduced seven products into the market since 2002, and over 65,000 patients worldwide have received ENDOTINE™ implants in facial rejuvenation procedures. The Company's products are sold in over 41 countries. Coapt Systems, founded in 2000 by a practicing plastic surgeon, designs, develops, manufactures, and markets bio absorbable implants that provide surgeons with breakthrough soft tissue fixation technology. Coapt's revolutionary platform technology for soft tissue fixation enables surgeons to reduce operating time, facilitate minimally invasive procedures, minimize procedural complexity, and achieve improved surgical outcomes. Coapt's patented ENDOTINE family of products are used for plastic surgery procedures that require accurate soft tissue fixation either to opposing soft tissue or to bone. The ENDOTINE product line is becoming the standard of care in aesthetic facial procedures. ”Coapt Systems has all the necessary elements, including strong management and an innovative product line, to continue its strong pace of growth and expansion,” said Brent Ahrens, general partner at Canaan Partners. ”Coapt is a great example of the type of innovative, high-growth company meeting unmet medical needs we invest in at Canaan. Laureen is a great addition to the team with her extensive management experience and recent success in the growing field of non-invasive aesthetics. Under her leadership, Coapt is poised to achieve even greater success moving forward.” Prior to joining Thermage in 2003, DeBuono was a consulting EVP and CFO to several public and private technology and medical device companies. DeBuono was also EVP, COO and CFO of More.com, an Internet health products commerce company, and she was EVP, COO and CFO of Resound Corporation, a public, hearing products and communications company that was acquired by GN Great Nordic in 1999. She also served as EVP, General Counsel to Nellcor Puritan Bennett Inc., a $900M public respiratory products company, from 1992-1998, and negotiated the sale of the company to Mallinkcrodt, Inc. in 1998. She was a member of the Board of Directors of Invivo, Inc., a public patient safety monitoring company, from 1998-2004, and of VISX, Inc., a public vision correction company, from 2003-2005, both of which were acquired. DeBuono received her J.D. from New York University Law School, an M.A. from Stanford University and a B.A. from Duke University. About Coapt Systems For further information, visit www.coaptsystems.com. Coapt Systems Launches ENDOTINE Ribbon For Immediate Release: September 14, 2006 (Palo Alto), California –Coapt Systems, Inc., developer of bioabsorbable implants for the fixation of soft tissue in the plastic and reconstructive surgery markets, announced today that it released the Endotine Ribbon for commercial sale in the U.S. market at the American Association of Facial Plastic and Reconstructive Surgery congress held in Toronto, Canada on September 14-17. "This is the second in a series of minimally invasive products that we plan to introduce. This product will enable us to address the needs of patients who desire the benefits of a jowl or neck lift without undergoing an extensive or highly invasive procedure. While the Ribbon can be employed in conventional facelift procedures, we believe many patients are searching for an option that can be combined with tiny incision approaches," said John Kraczkowsky, Senior Vice President, Sales and Marketing. "Currently, there are few options that are minimally invasive and that truly deliver lasting results like those seen with a Ribbon Lift." According to the American Society of Aesthetic and Plastic Surgery (ASAPS), over 200,000 facelift procedures were performed in the U.S. in 2005. The Ribbon Lift is highly desirable for patients who seek lower facial rejuvenation without significant downtime. According to Dr. David Apfelberg, Medical Director for Coapt Systems, "Patients who desire refinement to previous open facelifts are excellent candidates for a minimally invasive Ribbon Lift." Dr. Miles Graivier, who presented from the podium on early results with the Ribbon device at the prestigious Baker Gordon Plastic Surgery Symposium in February states, "The Ribbon is highly versatile in a number of surgical approaches and procedures. I am achieving results in jowl and neck sculpting that I have not seen with other minimally invasive methods.” Endotine Ribbon is now available throughout the U.S. About Coapt Systems For further information, visit www.coaptsystems.com. Coapt Systems Launches SurgiWire™ Incisionless Dissector For Immediate Release: February 8, 2006 (Palo Alto), California – Coapt Systems, Inc., developer of bioabsorbable implants for the fixation of soft tissue in the plastic and reconstructive surgery markets, announced today that it released the SurgiWire Incisionless Dissector for commercial sale in the U.S. market at the prestigious Baker Gordon Symposium held in Miami, Florida on February 2nd through the 4th. “This is the first in a series of minimally invasive products that we plan to introduce. This product will enable us to address the needs of patients who desire the removal of deep skin defects, such as wrinkles between the brow, the creases that run between the nose and mouth, and facial scars, with only a few needle punctures,” said John Kraczkowsky, Senior Vice President, Sales and Marketing. “A considerable number of patients who would prefer cosmetic fillers to correct these defects are not ideal candidates for fillers alone due to the depth of the skin defects.” According to the American Society for Aesthetic Plastic Surgery (ASAPS), over 3 million filler procedures were performed in the U.S. in 2004. The SurgiWire™ device is highly desirable for patients who seek skin rejuvenation of deep lines and scars without significant downtime. According to Dr. David Apfelberg, Medical Director for Coapt Systems, “These patients previously had to resort to more invasive means to correct these problems.” Dr. Miles Graivier, a national authority on wire dissection who presented from the podium on the topic at Baker Gordon states, “SurgiWire achieves excellent cosmetic results by separating dermal imperfections from their underlying attachments. I can use fillers such as fat or synthetic agents to supplement the results of the device, but the SurgiWire Release works so well that fillers are not always needed.” SurgiWire™ is now available throughout the U.S. About Coapt Systems For further information, visit www.coaptsystems.com. Coapt Systems Launches ENDOTINE Midface™ Bone 4.5 for Vertical Midface Suspension For Immediate Release: October 14, 2005 (Palo Alto), California – Coapt Systems, Inc., developer of bioabsorbable implants for the fixation of soft tissue in the plastic and reconstructive surgery markets, announced today that it has released the ENDOTINE Midface Bone 4.5 for commercial sale in the U.S. market to coincide with the annual congress of the American Society of OculoPlastic and Reconstructive Surgeons (ASOPRS) that took place in Chicago, Illinois. “This product is the fifth in a series of new products that we will launch over the next twelve months that will enable us to build an enduring franchise in the plastic surgery market,” said John Kraczkowsky, Senior Vice President, Sales and Marketing. “The ENDOTINE Midface Bone product provides our customers with another option to suspend the midface that has many advantages when compared to prior suspension techniques. This new device completes our midface product offering, now enabling surgeons to elevate the cheek in any direction from vertical to oblique.” According to the ASAPS, there were 157,000 facelifts performed in the U.S. last year, many of which involve a midface lift. The midface lift is one of the most rapidly growing segments of the facelift market as baby boomers seek a less invasive, more subtle change in their appearance. By eliminating the need for fixation sutures which are the most commonly used devices for midface suspension, surgeons find the ENDOTINE Midface much simpler and easier to use. It is well known that while suture suspension is effective in experienced hands, it also carries with it potential challenges, such as nerve entrapment, dimpling of tissue, tissue tear-through, extended O.R. time and surgeon frustration with lack of ability to adjust placement. According to Dr. John Zimmermann, of Napa, California, one of the first surgeons in the U.S. to implant the new device, “the Midface Bone device can be placed quickly through a lower blepharoplasty incision, and provides secure cheek elevation to restore a youthful look to the face. Patients are very satisfied with the aesthetic results of the procedure.” The ENDOTINE Midface Bone is now available throughout the U.S. Coapt plans to introduce the Midface Bone device overseas later this year. About Coapt Systems The company is also developing products for hand tendon and scapholunate repair. Located in Palo Alto, California, Coapt Systems, Inc. is a privately held company with 45 employees. For further information, visit www.coaptsystems.com. Coapt Systems Launches
ENDOTINE® Triple™ For Immediate Release: February 7, 2005 (Palo Alto), California – Coapt Systems, Inc., developer of bioabsorbable implants for the fixation of soft tissue in the plastic and reconstructive surgery markets, announced today that it has released the ENDOTINE Triple device for commercial sale in the U.S. market. “The Endotine Triple is the third in a series of products that we plan to introduce this year. This product will enable us to expand the number of browlift patients that could benefit from our products,” said John Kraczkowsky, Senior Vice President, Sales and Marketing. “The ENDOTINE Triple device accomplishes the same long-lasting result as our original forehead product, with a considerably smaller profile to reduce patient sensitivity and minimize incision length. It is designed to meet the needs of aesthetic patients who increasingly demand less invasive, less intrusive treatments.” According to, over 95,000 forehead lifts were performed in the U.S. last year. The Triple device is highly desirable for the patients who seek forehead rejuvenation without significant downtime. The new Triple device has a thinner platform, 60% less total mass, and only three tines versus the traditional forehead implant which has five tines. According to Dr. David Apfelberg, Chairman of Coapt’s Medical Advisory Board, “The ENDOTINE Triple is ideal for sensitive patients whose post operative comfort may be affected by device palpability; for busy, active patients who demand a rapid recovery; and for patients with receding, high or thin hairlines.” The ENDOTINE Triple is now available throughout the U.S. and Coapt plans to introduce the product to Europe in the second quarter of the year. About Coapt Systems For further information, visit www.coaptsystems.com. Coapt Systems Launches
ENDOTINE® TransBleph™ For Immediate Release: February 22, 2005 (Palo Alto), California – Coapt Systems, Inc., developer of bioabsorbable implants for the fixation of soft tissue in the plastic and reconstructive surgery markets, announced today that it has released the ENDOTINE TransBleph device for commercial sale in all U.S. markets. The ENDOTINE TransBleph received FDA clearance in November, 2004. “This product is the fourth in a series of products that we plan to introduce over the next twelve months that will enable us to continue to meet the needs of our surgeon customers in the plastic surgery market,” said John Kraczkowsky, Senior Vice President, Sales and Marketing. “The ENDOTINE TransBleph device represents a significant advance in that it allows a surgeon to perform a browlift and upper lid rejuvenation through a single incision without the need for an endoscope, using only local anesthesia.” There are nearly 400,000 facelifts performed worldwide each year, often in conjunction with a browlift. In addition, there are approximately 350,000 upper eyelid procedures performed annually, which ideally are performed with a browlift to yield longer lasting results. While baby boomers seek a less invasive, more subtle change in their appearance, currently available products have failed to meet physicians’ and patients’ expectations. Dr. Sterling Baker, a board certified oculoplastic surgeon with extensive experience implanting the TransBleph device, recently hosted an educational seminar to teach surgeons how to use the new product. According to Dr. Baker, “The ENDOTINE implant is designed to provide a simplified, but effective procedure to correct brow ptosis and upper lid tissue laxity while achieving excellent results through a single upper eyelid incision.” According to Dr. David Apfelberg, chairman of Coapt’s medical advisory board, “The ENDOTINE TransBleph provides a solution for surgeons who believe that for many of their patients, a blepharoplasty performed in conjunction with a browpexy will yield the most enduring and cosmetically pleasing results. Currently, these surgeons avoid browpexy because of patient concerns with cost, recovery time and the risks of anesthesia. We believe this product will eliminate patient concerns and provide a high level of surgeon satisfaction in delivering a more ideal result.” The ENDOTINE TransBleph is now available throughout the U.S. and Coapt plans to introduce the product into European markets sometime this summer. About Coapt Systems For further information, visit www.coaptsystems.com. Coapt Systems Secures $12
Million In Series D Venture Funding For Immediate Release: May 27, 2004 (Palo Alto), California – Coapt Systems, Inc., developer of bioabsorbable implants for the fixation of soft tissue in the plastic, reconstructive and sports medicine markets, announced today that it has closed on its $12.2 million Series D round of financing. The financing, led by Boston Millennia Partners, includes additional investments from existing investors including Alta Partners, Asset Management Company, Canaan Partners, Foundation Medical Partners, Pacific Asset Partners, Spring Ridge Ventures, Sears Capital Management and Trellis Health Ventures. In addition, Rob Mashal, M.D., a Partner with Boston Millennia, joins the Coapt Systems Board of Directors. “We are pleased to announce the completion of this latest round of financing and the addition of Boston Millennia Partners,” said Tom Kanar, Chief Financial Officer of Coapt Systems. “The support received from both new and existing investors reflects an overwhelming confidence in our business model based on the revenue potential from existing products and the value of our product pipeline. We are particularly pleased to have Rob Mashal, join our board. We’re confident his experience and insight will prove to be a valuable asset for us.” “Coapt is an exciting opportunity because it has all the major elements for a successful medical device investment firmly in place – a novel technology with an established customer and revenue base, a strong product pipeline and a seasoned management team,” according to Dr. Mashal. “We look forward to working with the company and growing the business over the coming years.” The company expects to use the proceeds to accelerate ongoing product development efforts and strengthen the company’s intellectual property. The proceeds will also be used to support ongoing commercialization of the company’s Endotine line of soft tissue fixation products used in plastic surgery to enable minimally invasive procedures and provide enhanced aesthetic outcomes. About Coapt Systems For further information, visit www.coaptsystems.com. Coapt Systems Launches ENDOTINE
Midface™ ST 4.5 for Midface Suspension For Immediate Release: March 15, 2004 (Palo Alto), California – Coapt Systems, Inc., developer of bioabsorbable implants for the fixation of soft tissue in the plastic and reconstructive surgery markets, announced today that it has initiated commercialization of the ENDOTINE Midface ST 4.5 for midface suspension surgery. The ENDOTINE Midface received FDA clearance in October 2003 and has since undergone and completed an IRB–approved clinical evaluation. “This product is the second in a series of products that we plan to introduce over the next twelve months that will enable us to build an enduring franchise in the plastic surgery market,” said John Kraczkowsky, Senior Vice President, Sales and Marketing. “We’re especially excited about the ENDOTINE Midface product, because it addresses the challenge that so many of our customers have expressed regarding the shortcomings of current midface suspension techniques.” There are nearly 400,000 facelifts performed worldwide each year, many of which involve a midface lift. The midface lift is one of the most rapidly growing segments of the facelift market as baby boomers seek a less invasive, more subtle change in their appearance. “Many of my patients in the 35 to 50 age group are not looking for a radical makeover, but rather a more understated rejuvenation that brings them back seven to ten years”, said Dr. N.D. Moscoe, a board certified plastic and reconstructive surgeon from Austin, Texas. “Because this implant is designed to offer enhanced cheek volume while reducing the complexity of the procedure, I believe that many surgeons will begin to proactively market this as a major part of their facial practice.” According to Dr. Daniel Jacobs, company founder and practicing plastic surgeon, “the ENDOTINE Midface provides a logical alternative for surgeons frustrated with the limitations of suture based midface suspension techniques. These are cumbersome techniques that can be technically very challenging, oftentimes prolonging OR time and leading to sub-optimal outcomes.” By eliminating the need for fixation sutures, which are the most commonly used devices for midface suspension, surgeons find the ENDOTINE Midface much simpler and easier to use. And its absorbable tines capture and elevate the cheek, holding it in position until the soft tissues re-adhere to the cheek bone. The device then gradually absorbs until it is completely gone. The ENDOTINE Midface is now available throughout the U.S. Coapt plans
to introduce the product into many key international markets by the
end of the year. About Coapt Systems For further information, visit www.coaptsystems.com. Coapt Systems Receives CE Mark for ENDOTINE
Forehead Fixation Device FOR IMMEDIATE RELEASE: October 22, 2003 (Palo Alto), California – Coapt Systems, developers of bioabsorbable implants for use in soft tissue fixation during plastic surgery procedures, today announced it has received European CE Mark for its ENDOTINE Forehead fixation device, which previously received market clearance from the U.S. Food and Drug Association (FDA) in March of this year. This regulatory milestone clears the way for Coapt to market the product in Europe, providing cosmetic and reconstructive surgeons with an innovative device designed to improve aesthetic outcomes for their patients seeking Browlift surgery. "Coapt Systems is committed to innovation in plastic surgery and the development of novel devices that surgeons use to elevate the practice of plastic surgery," said John Kraczkowsky, Coapt’s senior vice president of sales and marketing. "With the CE Mark in place, we plan to partner with well–known distributors, leveraging their established business networks and inside knowledge of their markets to bring ENDOTINE Forehead to surgeons and patients across Europe." ENDOTINE Forehead is a simple, easy to use bioabsorbable device designed to create secure, sutureless soft tissue fixation during Browlift surgery, with the goal of allowing surgeons to reduce operating time, facilitate open and minimally invasive procedures, minimize procedural complexity and achieve improved surgical and aesthetic outcomes. "ENDOTINE Forehead was developed with the goal of providing plastic surgeons with a secure fixation of a patient’s brow tissue, while also enhancing aesthetic control of brow height and shape," said Daniel Jacobs, M.D., Coapt’s founder and chief technology officer. During a Browlift procedure, the plastic surgeon separates the forehead tissue from the bone and elevates it to increase the height of the eyebrow. ENDOTINE Forehead uses multiple points of contact to grasp and hold this tissue in place. This unique feature provides the plastic surgeon with the ability to make adjustments during surgery to ensure the elevation is appropriate and the shape of the brow is optimal, resulting in a more natural outcome. Currently, most Browlift surgeries are performed using suture-based fixation techniques or with metal screws, which can protrude visibly through the top of the scalp and must be removed post-surgery. This can result in alopecia (hair loss) due to hair follicles being damaged. ENDOTINE Forehead is placed under the skin, where it absorbs over time, eliminating the need for removal and minimizing the risk of hair loss. ENDOTINE Forehead is currently available throughout the U.S. by way of Coapt’s direct and independent sales force. Additionally, Coapt announced it has received the International Organization of Standardization’s 9001 (ISOEN 13485:1996) certification for its quality management programs. Operating under this globally recognized system will help ensure best practices across Coapt’s organization, enabling the company to deliver products and services that meet international quality standards. About Coapt Systems For further information, visit www.coaptsystems.com. Coapt Systems Secures $12 Million In Series C
Venture Funding. FOR IMMEDIATE RELEASE: February 7, 2003 (Palo Alto), California – Coapt Systems, Inc., developer of bioabsorbable implants for the fixation of soft tissue in the plastic, reconstructive and sports medicine markets, announced today that it has closed on its $12.2 million Series C round of financing. The financing, led by Canaan Partners, includes a new investment from Foundation Medical Partners, and additional investments from existing investors, including Alta Partners, Asset Management Company, Spring Ridge Ventures, Pacific Asset Partners, Trellis Health Ventures, and others. In addition, Brent Ahrens, a Principal with Canaan Partners, joins the Coapt Systems Board of Directors. "We believe Coapt Systems has the potential to be a "home run" among our medical device investments. It possesses the key element which we always look for in our investments – a unique, proprietary technology with multiple applications in a large, underserved market," according to Mr. Ahrens of Canaan Partners. "This is a company with a highly experienced management team which so far has executed their plan flawlessly." The company expects to use the proceeds to accelerate ongoing product development efforts and strengthen the company’ intellectual property. The proceeds will also be used to support initial commercialization of the company’ first product, the ENDOTINE™ Forehead, a product used by plastic surgeons to fixate forehead tissue during endoscopic Browlift surgery. About Coapt Systems For further information, visit www.coaptsystems.com Coapt Systems Announces BETA Release Of The
ENDOTINE™ Forehead 3.5 FOR IMMEDIATE RELEASE: August 22, 2002 (Palo Alto) – Coapt Systems, Inc., developer of bioabsorbable implants for the fixation of soft tissue in the plastic, reconstructive and sports medicine markets, announced today that it has initiated commercialization of the ENDOTINE Forehead 3.5 for cosmetic Browlift surgery. The company introduced the product at the Sixth Annual Symposium on the Latest Advances in Cosmetic Surgery of the Face held this week in Newport Beach, California. The market introduction of the ENDOTINE Forehead 3.5 follows its March, 2002 clearance by the U.S. Food and Drug Administration for commercial distribution. The ENDOTINE device is based on the company’s patented Multipoint Technology (MPT ™), which is a revolutionary solution to the problems associated with joining soft tissues. Unlike the traditional suture-based approach, which damages tissue with high concentrations of stress, the MPT approach engages tissue across a broad area of fixation, eliminating stress concentrations that can often lead to failure. “A major challenge that plastic surgeons encounter in endoscopic Browlifting is the problem of fixation,” according to Daniel Jacobs, M.D., Coapt President and Chief Executive Officer. “The ENDOTINE Forehead overcomes this difficulty by providing secure brow fixation which is the key to a successful outcome. The introduction of the ENDOTINE represents an important milestone in the advancement of the endoscopic browlift.” “Our market entry strategy is to implement a controlled beta release of our first product,” explained John Kraczkowsky, Senior Vice President of Sales and Marketing. “With the expansion of our product line in early 2003, we will have the ability to treat the vast majority of Browlift patients. At that point, we will launch nationwide.” The Company believes that with 300,000 browlifts performed worldwide each year, the market opportunity for this product is substantial. Rapid adoption will generate significant revenue, leaving the company well-positioned for launENDOTINE Ching follow-on products later in the year. About Coapt Systems For further information, visit www.coaptsystems.com |
|
|
|||
